In vitro drug resistance of clinical isolated Brucella against antimicrobial agents
| Autor: | Xiao Chen, Xiao–Ke Hao, Xiu–Li Xu, Pei–Hong Yang, Jia–Yun Liu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Fever Ceftazidime Microbial Sensitivity Tests Drug resistance Brucella Brucellosis Drug Administration Schedule Microbiology Anti-Infective Agents Brucella melitensis medicine Humans Medicine(all) Minimal inhibitory concentration biology business.industry Drug Resistance Microbial General Medicine Antimicrobial agents bacterial infections and mycoses biology.organism_classification Antimicrobial Arthralgia Treatment Outcome Amikacin Female Gentamicin business Rifampicin Follow-Up Studies medicine.drug |
| Zdroj: | Asian Pacific Journal of Tropical Medicine. 6:921-924 |
| ISSN: | 1995-7645 |
| Popis: | Objective To explore the antibiotic resistance of Brucella melitensis and instruct rational use of antimicrobial agents in clinical treatment of Brucella infection. Methods Bacteria were cultured and identified by BACTEC9120 and VITEK II automicrobic system. E–test was used to detect the minimal inhibitory concentration (MIC) of antimicrobial agents in the drug susceptivity experiment. Results A total of 19 brucella strains (all Brucella melitensis ) were isolated from 19 patients, who had fever between January 2010 and June 2012, and 17 samples were blood, one was bone marrow, the other sample was cerebrospinal fluid. The MIC range of ceftazidime was 2.0–8.0 mg/L, rifampicin was 0.06–2.0 mg/L, amikacin was 4.0–12.0 mg/L, levofloxacin was 2.0–8.0 mg/L, doxycycline was 8.0–32.0 mg/L, sulfamethoxazole–trimethoprim was 4.0–16.0 mg/L, ampicillin was 1.5–2.0 mg/L and gentamicin was 0.50–0.75 mg/L. Conclusions The drugs used in this experiment cover common drugs for treating Brcella. Meanwhile, the results are consistent with clinical efficacy. It is suggested personalized regimen according to patients' status in treatment of Brucella. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|